The use of peripheral blood stem cells as source for allogeneic stem cell transplantations is now more frequent than the use of bone-marrow cells. Long-term follow-up studies comparing the two groups are beginning to be presented, but more data is needed. The long-term quality of life and general mental and physical health is almost absent. Here we present our single-center study comparing the use of peripheral blood stem cells (PBSC) and bone marrow (BM) in allogeneic stem cell transplantation.From June 1994 until February 1999, 61 patients were transplanted with either PBSC (n=31) or BM (n=30). In 2011 35 were still alive and brought to our department for examination. Follow-up data was collected via two questionnaires (EORTC-QLQ-C30 and HAD), through anamnestic mapping, physical examination and blood tests. Overall survival (OS) was comparable, 17/30 in the PBSC-group and 18/31 in the BM-group. Relapserate still was more frequent in the BM-group (40% vs. 9,7%, P= 0,07). More patients still had chronic GvHD (33,3% vs. 17,6% P=0,3) and more patients had sequelae after GvHD (72,2% vs 35,3%) of the patients transplanted with PBSC. We found no difference in health related quality of life, depression and anxiety. Furthermore, there was no difference in organ-spesific blood samples.15 years after transplantation the difference between the group is still present regarding GvHD and relapse, but do not affect the overall survival, general health status and quality of life.